Accordingly, patients with malignant tumors (4.04 ± 0.14) produced higher level of IGFBP-3 in serum compared to patients with benign tumors (2.50 ± 0.15) (P < 0.0001) (Figure 6C). Here, IGFBP3 is linked to benign neoplasm.